[go: up one dir, main page]

EP2503996A2 - Compositions pharmaceutiques à libération contrôlée de galantamine - Google Patents

Compositions pharmaceutiques à libération contrôlée de galantamine

Info

Publication number
EP2503996A2
EP2503996A2 EP10812951.1A EP10812951A EP2503996A2 EP 2503996 A2 EP2503996 A2 EP 2503996A2 EP 10812951 A EP10812951 A EP 10812951A EP 2503996 A2 EP2503996 A2 EP 2503996A2
Authority
EP
European Patent Office
Prior art keywords
galantamine
composition
mini
tablets
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10812951.1A
Other languages
German (de)
English (en)
Inventor
Ashok Omray
Sandhya Rajendra Shenoy
Harish Tulsidutt Bhatt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
USV Pvt Ltd
Original Assignee
USV Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by USV Pvt Ltd filed Critical USV Pvt Ltd
Publication of EP2503996A2 publication Critical patent/EP2503996A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to controlled release pharmaceutical compositions of Galantamine and process of preparation of said compositions.
  • Galantamine is indicated for the treatment of mild to moderately severe dementia of the Alzheimer type.
  • Galantamine is a tertiary alkaloid and is a competitive and reversible inhibitor of acetylcholinesterase.
  • Galantamine hydrobromide is chemically (4aS,6R,8aS)-4a,5,9,10, l l ,12-hexahydro-3-methoxy-l l-methyl-6H-benzofuro 3a,3,2- efj [2]benzazepin-6-ol hydrobromide.
  • the empirical formula of Galantamine hydrobromide is Ci7H 2 iN0 3 .HBr and it has a molecular weight of 368.27.
  • Galantamine hydrobromide is a white to almost white powder and is sparingly soluble in water.
  • the structural formula for Galantamine hydrobromide is as represented in Formula I,
  • Galantamine hydrobromide is available in the form of tablets and capsules for the use in the treatment of Alzheimer's disease. Galantamine and its salts have also been employed in the treatment of a variety of disorders including alcoholism, nicotinic dependence and mania due to their affinity for nicotinic receptors and it is capable of passing the blood-brain barrier. Galantamine hydrobromide is marketed as Razadyne ® in US by Janssen pharmaceuticals and Reminyl ® in Europe by Shire pharmaceuticals.
  • Galantamine hydrobromide is also available in the form of extended release capsules and is marketed in United states by Janssen pharmaceuticals.
  • Galantamine hydrobromide extended release capsules (Innovator) are available as opaque hard gelatin extended-release capsules of 8 mg (white), 16 mg (pink), and 24 mg (caramel) containing Galantamine hydrobromide, equivalent to respectively 8, 16 and 24 mg Galantamine base.
  • the inactive ingredients include gelatin, diethyl phthalate, ethylcellulose, hypromellose, polyethylene glycol, titanium dioxide and sugar spheres (sucrose and starch).
  • the 16 mg capsule also contains red ferric oxide.
  • the 24 mg capsule also contains red ferric oxide and yellow ferric oxide.
  • the extended release capsules of Galantamine hydrobromide are marketed under the brand name 'Reminyl XL ® ' by Shire pharmaceuticals.
  • EP0236684 discloses the use of Galantamine or an analogue or a pharmaceutically acceptable acid addition salt thereof for preparing a medicament for the treatment of Alzheimer's disease or related dementias.
  • WO0038686 discloses a controlled release formulation containing Galantamine, wherein it includes particles comprising Galantamine or a pharmaceutically acceptable acid addition salts thereof, a water-soluble pharmaceutically acceptable additive and optionally other pharmaceutically acceptable additives. The particles are coated by a release rate controlling membrane coating.
  • CA1326632 discloses a sustained release formulation wherein the particles of Galantamine hydrobromide are coated with polyvinyl pyrrolidone or any other suitable coating agent that is soluble in the intestinal tract.
  • US2004/0097484 discloses once a day pharmaceutical composition of Galantamine hydrobromide comprising a gelling agent, such as water-soluble organic gums, natural clays, synthetic clays to form a controlled release dosage form, such as a matrix, or diffusion-controlled composition.
  • a gelling agent such as water-soluble organic gums, natural clays, synthetic clays to form a controlled release dosage form, such as a matrix, or diffusion-controlled composition.
  • WO2005048979 discloses process for preparation of modified release pharmaceutical composition consisting of casing comprising at least two micro tablets, which are coated with rate controlling agent(s) optionally in combination with auxiliary pharmaceutical additive(s), wherein each micro tablet comprises core particles comprising pharmaceutically active ingredient and rate controlling agent(s), said core particles optionally coated with rate controlling agent(s).
  • the inventors of the present invention have developed Galantamine controlled release compositions which overcome the above drawbacks of prior art.
  • One object of the present invention is to provide controlled release pharmaceutical compositions of Galantamine comprising a plurality of matrix mini tablets, each comprising the active ingredient Galantamine hydrobromide and pharmaceutically acceptable additives and capable of being quantitatively filled into an empty capsule shell.
  • Another object of the invention is to provide a process for preparation of controlled release pharmaceutical compositions of Galantamine, which utilizes the technique that controls the release of Galantamine and significantly reduces the side effect, associated with conventional immediate release dosage forms.
  • Another object of the invention is to provide a controlled release dosage form which is easy to prepare and economical and gives accurate dosing with better patient compliance.
  • Yet another object of the invention is to provide controlled release compositions of Galantamine that can be given twice a day or more preferably can be given once a day and that demonstrates reliable release rate and facilitated in-vivo absorption for desired period of time.
  • the present invention provides controlled release pharmaceutical compositions of Galantamine useful for the treatment of mild to moderately severe dementia of Alzheimer type.
  • said composition comprises a plurality of controlled release mini tablets; wherein the mini tablet is in the form of a matrix mini tablet, which may optionally have a non-functional coating.
  • the present invention provides controlled release pharmaceutical compositions comprising a plurality of matrix mini tablets, each comprising the active ingredient and pharmaceutically acceptable additives and capable of being quantitatively filled into an empty hard gelatin capsule shell, wherein each matrix mini tablet comprises:
  • release modifying agents selected from: (i) one or more water soluble materials;
  • the invention provides controlled release pharmaceutical compositions of Galantamine, wherein said composition is characterized by the absence of release rate modifying coating.
  • said compositions are characterized by the absence of a rate controlling polymer in the coat of the mini-tablet/pellet.
  • the invention provides controlled release pharmaceutical compositions of Galantamine, wherein said composition is characterized by the absence of an immediate release portion of the active ingredient Galantamine.
  • the invention provides controlled release pharmaceutical compositions comprising a plurality of matrix mini tablets, each comprising the active ingredient Galantamine and pharmaceutically acceptable additives and capable of being quantitatively filled into an empty hard gelatin capsule shell, wherein each matrix mini tablet comprises:
  • composition exhibits a dissolution profile such that up to 2 hours, not more than 60% of Galantamine hydrobromide is released; after 4 hours, about 50% to 80% of Galantamine hydrobromide is released; after 12 hours, not less than 80% of Galantamine hydrobromide is released at pH 6.5 Phosphate buffer using USP Type II apparatus at 50 revolutions per minute.
  • the invention provides controlled release pharmaceutical compositions comprising a plurality of matrix mini tablets, each comprising the active ingredient Galantamine and pharmaceutically acceptable additives and capable of being quantitatively filled into an empty hard gelatin capsule shell, wherein each matrix mini tablet comprises:
  • composition is characterized by the absence of release rate modifying coating;
  • composition is characterized by the absence of an immediate release portion of the active ingredient Galantamine;
  • composition exhibits a dissolution profile such that up to 2 hours, not more than 60% of Galantamine hydrobromide is released; after 4 hours, about 50% to 80%) of Galantamine hydrobromide is released; after 12 hours, not less than 80% of Galantamine hydrobromide is released at pH 6.5 Phosphate buffer using USP Type II apparatus at 50 revolutions per minute.
  • the present invention provides controlled release pharmaceutical compositions of Galantamine comprising a plurality of matrix mini tablets; said compositions having atleast one or more of the following characteristics:
  • composition is characterized by the absence of release rate modifying coating
  • composition is characterized by the absence of an immediate release
  • composition exhibits a dissolution profile such that up to 2 hours, not more than 60% of Galantamine hydrobromide is released; after 4 hours, about 50% to 80%) of Galantamine hydrobromide is released; after 12 hours, not less than 80% of Galantamine hydrobromide is released at pH 6.5 Phosphate buffer using USP Type II apparatus at 50 revolutions per minute.
  • the invention provides a process for preparation of matrix mini- tablet, said process comprising granulating Galantamine or a pharmaceutically acceptable salt thereof with atleast one release modifying agent to form a granulate mass; characterized in that the granulation of the mixture is carried out by hot melt granulation at a temperature of 40°C to 120°C.
  • the invention provides a process for preparation of controlled release compositions of Galantamine, said process comprising:
  • the invention provides a process for preparation of controlled release composition of Galantamine, said process comprising:
  • the present invention provides controlled release pharmaceutical compositions of Galantamine comprising a plurality of mini tablets. Said compositions are useful for the treatment of mild to moderately severe dementia of Alzheimer type.
  • the mini tablet is in the form of matrix mini tablet, which may optionally have a non-functional coating.
  • each discrete unit may optionally be coated with non-release modifying coat for physical appearance and/or to protect from moisture ingress in to the composition on stability.
  • the present invention provides controlled release compositions comprising the active ingredient Galantamine or a pharmaceutically acceptable salt thereof and at least one release modifying agent; wherein said composition comprises a plurality of matrix mini tablets.
  • the pharmaceutically acceptable salt is hydrobromide.
  • the present invention provides controlled release pharmaceutical compositions comprising a plurality of matrix mini tablets, each comprising the active ingredient and pharmaceutically acceptable additives and capable of being quantitatively filled into an empty hard gelatin capsule shell, wherein each matrix mini tablet comprises:
  • the invention provides controlled release pharmaceutical compositions comprising a plurality of matrix mini tablets, each comprising the active ingredient and pharmaceutically acceptable additives and capable of being quantitatively filled into an empty hard gelatin capsule shell, wherein each matrix mini tablet comprises:
  • the present invention provides controlled release pharmaceutical compositions of Galantamine, wherein said composition is characterized by the absence of release rate modifying coating.
  • said compositions are characterized by the absence of a rate controlling polymer in the coat of the mini-tablet/pellet.
  • the invention provides controlled release pharmaceutical compositions comprising a plurality of matrix mini tablets with optionally a non-functional coat and each comprising the active ingredient and pharmaceutically acceptable additives and capable of being quantitatively filled into an empty capsule shell, wherein each matrix mini tablet is characterized by the absence of release rate modifying coating and comprises:
  • release modifying agents selected from: (i) one or more water soluble materials;
  • the present invention provides controlled release pharmaceutical compositions of Galantamine, wherein said composition is characterized by the absence of an immediate release portion of the active ingredient Galantamine.
  • the invention provides controlled release pharmaceutical compositions comprising a plurality of matrix mini tablets with optionally a non-functional coat and each comprising the active ingredient and pharmaceutically acceptable additives and capable of being quantitatively filled into an empty capsule shell, wherein each matrix mini tablet is characterized by the absence of release rate modifying coating and comprises:
  • composition is characterized by the absence of an immediate release portion of the active ingredient Galantamine hydrobromide.
  • said controlled release compositions are provided in the form of capsule dosage form having no immediate release component of Galantamine hydrobromide.
  • the pharmaceutically active agent or the therapeutically active agent is released according to a desired profile over an extended period of time.
  • the controlled release pharmaceutical compositions of the present invention exhibit a dissolution profile such that up to 2 hours, not more than 60% of Galantamine hydrobromide is released; after 4 hours, about 50% to 80% of Galantamine hydrobromide is released; after 12 hours, not less than 80% of Galantamine hydrobromide is released at pH 6.5 Phosphate buffer using USP Type II apparatus ( paddle) at 50 rpm.
  • the invention provides controlled release pharmaceutical compositions comprising a plurality of matrix mini tablets, each comprising the active ingredient Galantamine and pharmaceutically acceptable additives and capable of being quantitatively filled into an empty hard gelatin capsule shell, wherein each matrix mini tablet comprises:
  • composition exhibits a dissolution profile such that up to 2 hours, not more than 60% of Galantamine hydrobromide is released; after 4 hours, about 50% to 80% of Galantamine hydrobromide is released; after 12 hours, not less than 80% of Galantamine hydrobromide is released at pH 6.5 Phosphate buffer using USP Type II apparatus at 50 revolutions per minute.
  • the invention provides controlled release pharmaceutical compositions comprising a plurality of matrix mini tablets, each comprising the active ingredient Galantamine and pharmaceutically acceptable additives and capable of being quantitatively filled into an empty hard gelatin capsule shell, wherein each matrix mini tablet comprises:
  • composition is characterized by the absence of release rate modifying coating;
  • composition is characterized by the absence of an immediate release portion of the active ingredient Galantamine;
  • composition exhibits a dissolution profile such that up to 2 hours, not more than 60% of Galantamine hydrobromide is released; after 4 hours, about 50% to 80% of Galantamine hydrobromide is released; after 12 hours, not less than 80% of Galantamine hydrobromide is released at pH 6.5 Phosphate buffer using USP Type II apparatus at 50 revolutions per minute.
  • the active ingredient is present in a micronized form.
  • Galantamine or pharmaceutically acceptable salt, hydrate or solvate thereof is in the form of micronized particles; wherein said micronized particles have a D90 particle size of less than 100 micron.
  • the micronized particles have a D90 particle size of less than 50 micron and more preferably between 10 and 40 micron.
  • the inventors have carefully done a selection of the particle size of the active ingredient so that an identical release profile with that of the innovator's clinically approved product is achieved.
  • the present invention provides controlled release pharmaceutical compositions of Galantamine comprising a plurality of matrix mini tablets; said compositions having atleast one or more of the following characteristics:
  • composition is characterized by the absence of release rate modifying coating
  • composition is characterized by the absence of an immediate release
  • composition exhibits a dissolution profile such that up to 2 hours, not more than 60% of Galantamine hydrobromide is released; after 4 hours, about 50% to 80% of Galantamine hydrobromide is released; after 12 hours, not less than 80% of Galantamine hydrobromide is released at pH 6.5 Phosphate buffer using USP Type II apparatus at 50 revolutions per minute.
  • Galantamine is present in an amount from 2.0% to 20% by weight of the total composition; preferably in an amount from 5.0% to 15% by weight of the total composition.
  • the ratio of Galantamine to release modifying agents is in the range of about 1 :1 to 1 :20; preferably 1 :2 to 1 : 15.
  • Mixtures of water soluble/water-swellable material with water-insoluble material may be employed in a weight ratio of about 10: 1 to 1 : 10, preferably 4: 1 to 1 :4.
  • the controlled release composition comprises of about 2% to about 25% by weight of Galantamine hydrobromide, about 30% to about 90% by weight of release modifying agent, about 10% to about 60% by weight of diluent, about 1% to about 10% by weight of binder, about 0.5% to about 5% by weight of lubricant, about 0.5% to about 5% by weight of glidant, about 2% to about 15% by weight of coating agents.
  • the controlled release composition comprises about 5% to about 20% by weight of Galantamine hydrobromide, about 40% to about 70% by weight of release modifying agent, 10% to about 30% by weight of diluent, about 2% to about 10% by weight of binder, about 0.5% to about 5% by weight of lubricant, about 0.5% to about 5%by weight of glidant, about 2% to about 10% by weight of coating agents.
  • matrix mini tablets equivalent to the desired weight of active ingredient is filled into the hard gelatin capsule or hard cellulose capsule. Empty hard gelatin capsule or empty hard cellulose capsules of size ranging from '4' to '0' may be used based on the desired weight of the formulation to be incorporated into the capsule dosage form.
  • the mini tablet may have a diameter from lmm to 3 mm and each capsule shell may contain a plurality of mini tablets ranging from 2 to 30. Tablets may be of various shape such as oval, elliptical, spherical or caplet shaped.
  • the controlled release compositions according to the present invention contain Galantamine in a dose range from 8mg to 24mg.
  • said compositions may contain Galantamine in doses such as 8mg, 16mg and 24mg.
  • Said compositions are recommended for once-a-day administration in order to achieve a controlled effect of the drug.
  • Controlled release compositions of present invention exhibit drug release profiles similar to marketed product Reminyl XL ® .
  • the release-modifying agents may be selected from one or more water-soluble materials and/or water-insoluble materials and/or water-swellable materials.
  • Water soluble materials which may be employed for the controlled release compositions include, but are not limited to polyethylene oxide (average molecular weight 1 ,00,000 to 50,00,000), sodium alginate, calcium ammonium alginate, potassium alginate, calcium alginate, celluloses such as hydroxypropyl methyl cellulose, propylene glycol alginate, polyvinyl alcohol, povidone, carbomers, xanthan gum, triethyl citrate, a co-polymer of vinylacetate and vinylpyrrolidone (Kollidon SR from BASF) and the like. Water-soluble materials may be present in an amount from 20% to 80% by weight of the total composition.
  • Water insoluble materials which may be employed for the controlled release compositions include, but are not limited to stearic acid, glyceryl monostearate, glyceryl behenate, ethyl cellulose, glyceryl palmitostearate, microcrystalline wax, polymethacrylate, stearyl alcohol, cetyl alcohol, cetostearyl alcohol, hydrogenated castor oil, polyvinyl acetate phthalate, waxes, shellac, tristearin, rosin, polyvinyl chloride powder or polyethylene powder, magnesium or aluminium silicates and the like and may be present in an amount from 20% to 80% by weight of the total composition.
  • Water-swellable materials which may be employed for the controlled release compositions include, but are not limited to alginic acid, guar gum and the like and may be present in an amount from 20% to 80% by weight of the total composition.
  • the present invention further provides a process for preparation of controlled release compositions of Galantamine or a pharmaceutically acceptable salt thereof.
  • the process for preparation of controlled release pharmaceutical compositions comprising a plurality of matrix mini tablets, each comprising the active ingredient Galantamine and pharmaceutically acceptable additives and capable of being quantitatively filled into an empty hard gelatin capsule shell, said process comprising:
  • the process for preparation of controlled release pharmaceutical compositions comprising a plurality of matrix mini tablets, each comprising the active ingredient Galantamine and pharmaceutically acceptable additives and capable of being quantitatively filled into an empty hard gelatin capsule shell, said process comprising:
  • the invention provides a process for preparation of Galantamine controlled release composition
  • a process for preparation of Galantamine controlled release composition comprising granulating Galantamine hydrobromide with atleast one release modifying agent to form a granulate mass; characterized in that the granulation of the mixture is carried out by hot melt granulation at a temperature of 40°C to 120°C.
  • the invention provides a process for preparation of mini-tablet, said process comprising granulating Galantamine or a pharmaceutically acceptable salt thereof with atleast one release modifying agent to form a granulate mass; characterized in that the granulation of the mixture is carried out by hot melt granulation at a temperature of 40°C to 120°C, sizing the granulate mass, blending the granules with pharmaceutically acceptable additives and compressing the blend into mini-tablets.
  • the invention provides a process for preparation of matrix mini-tablet, said process comprising granulating Galantamine or a pharmaceutically acceptable salt thereof with atleast one water insoluble material to form a granulate mass; characterized in that the granulation of the mixture is carried out by hot melt granulation at a temperature of 40°C to 120°C.
  • the process for preparation of controlled release compositions of Galantamine comprises:
  • step (ii) granulating the blend of step (i) by hot melt granulation or by extrusion to form a granulate mass
  • step (iii) optionally granulating the mass of step (iii) with an aqueous or organic solution of binder and drying;
  • step(iv) converting the mass of step(ii) or step(iii) into granules by milling and sizing
  • the process for preparation of controlled release pharmaceutical compositions comprising a plurality of matrix mini tablets, each comprising the active ingredient Galantamine and pharmaceutically acceptable additives and capable of being quantitatively filled into an empty hard gelatin capsule shell, said process comprising:
  • the process for preparation of Galantamine controlled release composition comprises the steps of:
  • step (b) preparing a binder solution by dissolving the binder in a suitable solvent; c) granulating the blend of step (a) with binder solution of step (b) to form desired wet mass;
  • step(c) screening the wet mass of step(c) to form granules
  • step (d) drying the granules of step (d) till loss on drying in the range of 0.5% to 5.0% is achieved;
  • step (e) sizing the dried granules of step (e).
  • step (ii) mixing the intra-granular composition of step (i) with an extra-granular composition containing anti-adherents and optionally one or more release modifying agents to form a granule blend;
  • step (iii) lubricating the granule blend of step (ii) with suitable lubricants
  • step (iv) compressing the lubricated granules of step (iii) into mini-tablets using suitable compression machine fitted with punches and dies;
  • the mini tablets may also be prepared by direct compression, slugging/deslugging, wet granulation or hot melt extrusion method.
  • the process for preparation of controlled release pharmaceutical compositions of Galantamine according to the present invention has the following advantages: (1) The process is easy and economical in comparison to prior art processes.
  • the process for preparation of controlled release pharmaceutical compositions of Galantamine according to the present invention utilizes the technique that controls the release of Galantamine and significantly reduces the side effect, associated with conventional immediate release dosage forms.
  • Said controlled release compositions of Galantamine can be given twice a day or more preferably can be given once a day.
  • Said compositions demonstrate reliable release rate and facilitated in-vivo absorption for desired period of time.
  • the process for preparation of Galantamine controlled release composition comprises the steps of:
  • step (2) mixing the blend of step (1) with anti-adherents and finally lubricating the blend with suitable lubricants;
  • step (3) compressing the lubricated granules of step (2) into mini-tablets using a compression machine fitted with suitable punches and dies;
  • the process for preparation of Galantamine controlled release composition comprises the steps of:
  • step (iii) granulating the blend of step (i) with binder solution of step (ii) to form desired wet mass
  • step (iv) screening the wet mass of step (iii) through extrusion of suitable sized screen to get extrudes of desire strength;
  • step (v) optionally subjecting the extrudes of step (iv) to spheronization using suitable friction plates combination to get desired size distribution of particles;
  • step (vi) drying the above particles or spheres of step (v) till loss on drying in the range of 0.5% to 5.0% is achieved;
  • a method for treating alzheimer's disease by administering the controlled release compositions comprising Galantamine or salt thereof to patients in need.
  • Suitable pharmaceutically acceptable additives that may be used for formulation include, but are not limited to, diluents/fillers, binders, glidants/anti-adherants, lubricants, non-release modifying/non-functional coating agents and the like.
  • Diluents that can be used as per the invention include, but are not limited to calcium hydrogen phosphate, tribasic calcium phosphate, calcium carbonate, lactose, microcrystalline cellulose, magnesium carbonate, magnesium oxide or mixtures thereof and is present in an amount from about 10% to about 60% by weight of the total composition.
  • Binders that can be used as per the invention include, but are not limited to polyvinyl pyrrolidone, gelatin, polyvinyl alcohol, gum acacia and the like and is present in an amount from about 1.0% to about 15% by weight of the total composition.
  • Solvents that can be used as per the invention, include, isopropyl alcohol, methylene chloride, water or mixtures thereof in an amount sufficient to dissolve the binder.
  • Anti-adherents that can be used as per the invention include, but are not limited to colloidal silicon dioxide, talc, starch and the like and is present in an amount up to 3.0% by weight of the total composition.
  • Lubricants that can be used as per the invention include, but are not limited to magnesium stearate, calcium stearate, zinc stearate and the like and is present in an amount up to 3.0% by weight of the total composition.
  • Controlled release compositions particularly the mini-tablets/pellets prepared by the process as described herein may be further film coated using non-functional coating composition employing any of the conventional coating techniques like pan coating, spray coating etc. Tablet coat of 2-10% with respect to total weight can be employed to make mini tablets aesthetically pleasing and allow the smooth flow from capsule filling machine.
  • Non-functional film coating may be carried out using one or more additives selected from the group comprising film formers, opacifiers, coating agents, taste-masking agents, colouring agents, antitacking agents and the like.
  • Film formers such as hydroxypropyl cellulose or hydroxypropyl methyl celluloses or the like can be used.
  • Opacifying agents include titanium dioxide, ferric oxide, sunset yellow and the like.
  • Plasticizers such as polyethylene derivatives, polyethylene glycol, propylene glycol, triethyl citrate and the like can be used.
  • Antitacking agents include talc, stearic acid, magnesium stearate, colloidal silicon dioxide and the like.
  • Non-functional film coating can be used in concentrations which are well known to a person skilled in the art.
  • Non-functional coating may also be carried out using readymade coating composition available as Opadry, Kollicoat (Graft copolymer of polyvinyl alcohol-polyethylene glycol) and the like.
  • Non-functional film coating serves the purpose of taste neutralization, moisture protection and provides elegance to the mini tablets.
  • Granulation may be carried out using high shear mixer or by spray granulation technique. Mixing and granulation can be carried out in a conventional rapid mixer granulator and the wet granules can be further dried using fluid bed drier. High shear granulation improves the cohesiveness of particles and provides excellent flowability and compression characteristics to the tablet. As the granules exhibit good flow properties, mini tablets produced possess uniformity in weight.
  • aqueous/non-aqueous granulation is carried out by adding the binder slowly in a thin stream continuously using a peristaltic pump under high speed mixing with the impeller 'on' and chopper Off'. On completion of binder addition, mixing is continued at high impeller speed till cohesive granular mass is obtained. If the mass is lumpy then chopper may be used at high speed with impeller also at high speed to obtain uniform wet mass. Drying of granulated mass may be carried out using fluidized bed drier or tray drier. Granulated mass is dried for sufficient time till loss on drying value in the range of about 0.5% to about 3.0% is achieved.
  • both the steps of granulation and drying can be carried out in the same equipment thereby simplifying the process and saving the processing time.
  • Compression may be carried out using equipments known in the art such as a rotary tablet press or any suitable tabletting machine fitted with suitable size punches and dies.
  • Coating may be carried out using equipments known in the art such as spray coating or coating in conventional coating pan or perforated pans.
  • compositions prepared by the process as described herein withstand the accelerated stability conditions of temperature and relative humidity and maintain their physical and chemical integrity at accelerated conditions of stability.
  • Controlled release pharmaceutical composition of Galantamine provides the following advantages over the immediate release oral pharmaceutical form,
  • Controlled release compositions prepared according to the present invention shows the following in-vitro drug release characteristics when tested in pH 6.5 phosphate buffer for the 1, 4 and 12 hours.
  • controlled release refers to the release of the active ingredient according to a desired profile over an extended period of time.
  • additives refers to a pharmaceutically acceptable ingredient that is commonly used in the pharmaceutical technology for preparing granules and/or solid oral pharmaceutical dosage forms.
  • mini-tablet is intended to encompass compressed pharmaceutical formulat ions of all shapes, whether coated or uncoated.
  • Galantamine hydrobromide (20.5 g), calcium hydrogen phosphate dihydrate (21.5g), microcrystalline cellulose [Avicel PH 102] (4.0 g), carbomer [Carbopol 71G] (60 g) and polyethylene oxide [Polyox WSR N 303] were sifted and mixed.
  • the mixed blend was lubricated with magnesium stearate (2.0 g) and compressed into mini-tablets of size 1 to 3 mm. Compressed mini-tablets were coated by dispersing opadry (HPMC based) in non-aqueous vehicles to get uniform surface for controlled release mini tablets. Tablets were coated till a weight gain of about 1-10% was achieved. Finally the mini-tablets were filled in required size capsules.
  • Galantamine hydrobromide (38.52g), lactose monohydrate (236.48g), microcrystalline cellulose (105 g), and polymethacrylate [Eudragit RLPO] (100.0 g) were mixed and granulated using binder solution containing hydroxypropyl cellulose (20.0 g) dissolved in purified water (180.0 g).
  • the resultant mass was extruded and spheronised and the spherical particles were dried using rapid dryer. The dried particles were coated with non-functional coating agent and filled into capsules of required size.
  • Stearic acid (71.19 g) was melted at 60°C.
  • Galantamine hydrobromide (30.81 g) was heated to 60°C in a jacketed rapid mixer granulator and granulated with the melted stearic acid at 60°C. After granulation the mass was mixed continuously till it cools to room temperature and dry mass was milled to required size.
  • Sized granules were blended with ollidOn SR (55.16 g) (Kollidon SR is a co-polymer of polyvinyl acetate and polyvinyl pyrrolidone), microcrystalline cellulose [Avicel PH 102] (1.45 g) and magnesium stearate (1.45 g). Compressed the blended granules into mini- tablets of size 1 to 3 mm. Compressed mini-tablets were coated with non- functional coating agent and filled into capsules of required size.
  • Stearic acid (95.19 g) was melted at 60°C.
  • Galantamine hydrobromide (30.81 g) was heated to 60°C in a jacketed rapid mixer granulator and granulated with the melted stearic acid at 60°C. After granulation the mass was mixed continuously till it cools to room temperature and dry mass was milled to required size.
  • Xanthan gum (98.98 g) was separately granulated with binder solution of povidone (2.95g) in isopropyl alcohol (30.0ml). The wet mass was dried till the desired loss on drying value was achieved.
  • the dried Galantamine granules were mixed with the Xanthan gum granules and further lubricated with magnesium stearate (1.44g). Compressed the blended granules into mini-tablets of size 1 to 3 mm. Compressed mini-tablets were coated with non-functional coating agent and filled into capsules of required size.
  • Stearic acid (47.46 g) was melted at 60°C.
  • Galantamine hydrobromide (20.54 g) was heated to 60°C in a jacketed rapid mixer granulator and granulated with the melted stearic acid at 60°C. After granulation the mass was mixed continuously till it cools to room temperature and dry mass was milled to required size. Sized granules were blended with dicalcium phosphate (1 1.74 g), sodium alginate (107.57 g) and magnesium stearate (1 .96 g). Compressed the blended granules into mini-tablets of size 1 to 3 mm. Compressed mini-tablets were coated with non-functional coating agent and filled into capsules of required size.
  • Galantamine hydrobromide (30.81 g), microcrystalline cellulose [Avicel PH 101] (83.19 g), and hypromellose [Methocel K100M] (120.0 g) were mixed and granulated using binder solution containing stearic acid (15.0 g) dissolved in isopropyl alcohol (81.9 g). The resultant mass was dried to get loss on drying value between 0.5-3.0%. The dried mass was mixed with Kollidon SR (57.0 g), talc (1.5 g) and magnesium stearate (1.5 g) in a blender and compressed into mini-tablets of size 1 to 3 mm. Compressed mini-tablets were coated with non-functional coating agent and filled into capsules of required size.
  • Hydrogenated castor oil (98.75g) was melted at 85°C.
  • Galantamine hydrobromide 51.31g
  • microcrystaliine cellulose 69.94g
  • ethyl cellulose 130.00g
  • Galantamine hydrobromide 51.31g
  • microcrystaliine cellulose 69.94g
  • ethyl cellulose 130.00g
  • Compressed mini-tablets were coated with a non functional coat of Kollidon IR and the mini-tablets were filled into hard gelatin capsules of required size.
  • Table 1 summarizes the in-vitro dissolution profile for the controlled release Galantamine hydrobromide capsules prepared according to Example 7 of the present invention versus Reminyl XL ® (Innovator's Galantamine hydrobromide prolonged release capsules). Dissolution was carried out in phosphate buffer pH 6.5 using USP Type II (paddle), at 50 rpm.
  • AUCo-t Area under the plasma concentration versus time curve, from time zero to the last measurable concentration.
  • AUCo-inf Area under the plasma concentration versus time curve, from time zero to infinity.
  • Controlled release Galantamine hydrobromide capsules prepared according to Example 7 is bio-equivalent to reference product (Reminyl XL ® ) when tested in-vivo on healthy, adult, human subjects under fasting and fed conditions. Stability study:
  • Controlled release compositions of Galantamine hydrobromide prepared according to Example 7 were subjected to stability studies at 40°C and 75% relative humidity (RH) for 6 months.
  • Table 3 shows the results of Stability study.
  • Hydrogenated castor oil (59.00g) and stearic acid (20.00g) was melted at 85°C.
  • Galantamine hydrobromide (41.07g), microcrystaliine cellulose (55.93g), and ethyl cellulose (104. OOg) was heated to 85°C in a jacketed rapid mixer granulator and granulated with the mixture of molten hydrogenated castor oil and stearic acid at 85°C and further mixed continuously till it cools to room temperature and the solidified mass was milled to granules of required size and further lubricated with magnesium stearate (8. OOg).
  • Compressed mini-tablets were filled into hard gelatin capsules of required size.
  • Table 4 summarizes the invitro-dissolution profile for the controlled release Galantamine hydrobromide capsules prepared according to Example 8 of the present invention versus Reminyl XL ® (Innovator's Galantamine hydrobromide prolonged release capsules). Dissolution was carried out in phosphate buffer pH 6.5 using USP Type II (paddle), at 50 rpm. Table 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques à libération contrôlée de galantamine comprenant une pluralité de mini comprimés matriciels contenant de la galantamine ou son sel pharmaceutiquement acceptable et au moins un agent de modification de la libération. Les compositions selon l'invention sont caractérisées par l'absence de revêtement modifiant la vitesse de libération et/ou par l'absence d'une partie à libération intermédiaire de la galantamine.
EP10812951.1A 2009-11-26 2010-11-26 Compositions pharmaceutiques à libération contrôlée de galantamine Withdrawn EP2503996A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2736MU2009 2009-11-26
PCT/IN2010/000767 WO2011064797A2 (fr) 2009-11-26 2010-11-26 Compositions pharmaceutiques à libération contrôlée de galantamine

Publications (1)

Publication Number Publication Date
EP2503996A2 true EP2503996A2 (fr) 2012-10-03

Family

ID=44067021

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10812951.1A Withdrawn EP2503996A2 (fr) 2009-11-26 2010-11-26 Compositions pharmaceutiques à libération contrôlée de galantamine

Country Status (4)

Country Link
EP (1) EP2503996A2 (fr)
BR (1) BR112012012766A2 (fr)
CA (1) CA2781826A1 (fr)
WO (1) WO2011064797A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1007767B (el) * 2011-07-26 2012-11-19 Φαρματεν Αβεε, Φαρμακευτικο σκευασμα παρατεταμενης αποδεσμευσης περιεχον γκαλανταμινη και μεθοδος για την παρασκευη αυτου
US10105320B2 (en) * 2013-10-03 2018-10-23 Altria Client Services Soluble fiber lozenge
BG67408B1 (bg) 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости
CN113384536B (zh) * 2020-03-14 2024-04-02 鲁南制药集团股份有限公司 一种注射用双羟萘酸加兰他敏缓释微粒及其制备方法
US12208167B1 (en) * 2024-02-06 2025-01-28 Alpha Cognition Inc. Coated tablets for pH-dependent release of benzgalantamine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
CA1326632C (fr) 1988-10-26 1994-02-01 Bonnie Davis Compositions pharmaceutiques a action prolongee contenant de la galanthamine pour le traitement de la maladie d'alzheimer
HUP0104778A3 (en) 1998-12-24 2004-05-28 Janssen Pharmaceutica Nv Controlled release galantamine composition
US20040097484A1 (en) 2002-11-14 2004-05-20 Marc Cantillion Once a day galantamine pharmaceutical compositions and methods of use
WO2005048979A2 (fr) 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Composition pharmaceutique avec capsule pour microtablettes multiples
WO2009024858A1 (fr) * 2007-08-22 2009-02-26 Aurobindo Pharma Limited Forme posologique à libération contrôlée de galantamine
EA201000585A1 (ru) * 2007-10-05 2010-10-29 КРКА, д.д., НОВО МЕСТО Многочастичная матричная система, содержащая галантамин
EP2044933A1 (fr) * 2007-10-05 2009-04-08 KRKA, D.D., Novo Mesto Système de matrice à multi-particules contenant de la galantamine
EP2116232B1 (fr) * 2008-05-09 2012-02-15 Ratiopharm GmbH Médicament à libération contrôlée comprenant de la galanthamine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011064797A2 *

Also Published As

Publication number Publication date
CA2781826A1 (fr) 2011-06-03
BR112012012766A2 (pt) 2016-09-06
WO2011064797A2 (fr) 2011-06-03
WO2011064797A3 (fr) 2012-04-12

Similar Documents

Publication Publication Date Title
CA2798178C (fr) Formulations a liberation immediate et formes pharmaceutiques de gamma-hydroxybutyrate
CA2604617C (fr) Composition renfermant une drogue contre la demence
TWI590835B (zh) 含有氫嗎啡酮（ｈｙｄｒｏｍｏｒｐｈｏｎｅ）和納洛酮（ｎａｌｏｘｏｎｅ）之藥學組成物
US20070059365A1 (en) Novel formulation of ropinirole
EP2187874A2 (fr) Compositions à libération prolongée de trimétazidine et procédé de préparation
US20110300209A1 (en) Modified release solid pharmaceutical compositions of trimetazidine and process thereof
EP2503996A2 (fr) Compositions pharmaceutiques à libération contrôlée de galantamine
JP7021108B2 (ja) ニコチンアミドの経口薬学的組成物
EP2533766A2 (fr) Mini-pastilles pharmaceutiques destinées à la libération prolongée d'acétate de flécaïnide
AU2014295098B2 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
WO2006103551A1 (fr) Formulations d’oxycodone a liberation controlee
EP3796908B1 (fr) Formulations de propivérine à libération contrôlée
WO2006123213A1 (fr) Preparations a liberation modifiee de gliclazide
CA3238807A1 (fr) Formulations a liberation controlee de flavoxate et procede de preparation de celles-ci
JP2009525953A (ja) ジバルプロ酸及びその誘導体の徐放性製剤
US20140341990A1 (en) Controlled Release Formulations of Nisoldipine
OA16241A (en) Pharmaceutical compositions comprising hydromorphone and naloxone.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120625

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130601